Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AXSM Axsome Therapeutics, Inc.

盘后交易 10-21 17:59:17 EDT

156.31

-3.27

-2.05%

盘后156.50

+0.19+0.12%

17:02 EDT

最高160.82	最低156.04	成交量52.48万
今开158.83	昨收159.58	日振幅2.99%
总市值81.88亿	流通市值68.51亿	总股本5,238万
成交额8,264万	换手率1.20%	流通股本4,383万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AXSM","market":"US","secType":"STK","nameCN":"Axsome Therapeutics, Inc.","latestPrice":156.31,"timestamp":1792612800000,"preClose":159.58,"halted":0,"volume":524756,"hourTrading":{"tag":"盘后","latestPrice":156.5,"preClose":156.31,"latestTime":"17:02 EDT","volume":8339,"amount":1303508.86703,"timestamp":1792616520536,"change":0.19,"changeRate":0.001216,"amplitude":0.010812},"delay":0,"changeRate":-0.020491289635292707,"floatShares":43831415,"shares":52380818,"eps":-3.768492,"marketStatus":"盘后交易","change":-3.27,"latestTime":"10-21 17:59:17 EDT","open":158.83,"high":160.8175,"low":156.04,"amount":82635106.24283999,"amplitude":0.029938,"askPrice":159,"askSize":200,"bidPrice":156,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.768492,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1792627200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1447909200000,"exchange":"NASDAQ","adjPreClose":159.58,"preHourTrading":{"tag":"盘前","latestPrice":158.83,"preClose":159.58,"latestTime":"09:29 EDT","volume":504,"amount":80033.82408,"timestamp":1792589399999,"change":-0.75,"changeRate":-0.0047,"amplitude":0.034904},"postHourTrading":{"tag":"盘后","latestPrice":156.5,"preClose":156.31,"latestTime":"17:02 EDT","volume":8339,"amount":1303508.86703,"timestamp":1792616520536,"change":0.19,"changeRate":0.001216,"amplitude":0.010812},"volumeRatio":0.655187,"impliedVol":0.5892,"impliedVolPercentile":0.8805},"requestUrl":"/m/hq/s/AXSM","defaultTab":"news","newsList":[{"id":"1112855441","title":"异动解读｜Axsome Therapeutics盘中下跌5.46%，德银下调目标价叠加获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1112855441","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112855441?lang=zh_cn&edition=full","pubTime":"2026-09-30 02:03","pubTimestamp":1790704984,"startTime":"0","endTime":"0","summary":"9月30日，Axsome Therapeutics盘中下跌5.46%，报183.31美元/股，成交额1.48亿美元。消息面上，德意志银行将Axsome Therapeutics目标价从280美元下调至267美元，虽维持买入评级，但目标价下修信号或引发市场短期情绪波动。此前Truist曾大幅上调目标价至285美元，瑞穗维持316美元目标价并指出Auvelity在阿尔茨海默病激越适应症的处方数据保持两位数增长。尽管分析师共识目标价仍维持在282.52美元，但公司此前两季度EPS均不及预期，叠加股价前期累积一定涨幅，短期获利回吐压力显现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"德银下调目标价，Axsome股价承压","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182767493","title":"异动解读｜Axsome Therapeutics盘中上涨6.24%，Auvelity处方量强劲增长提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1182767493","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182767493?lang=zh_cn&edition=full","pubTime":"2026-09-12 00:13","pubTimestamp":1789143207,"startTime":"0","endTime":"0","summary":"9月12日，Axsome Therapeutics盘中上涨6.24%，报224.28美元/股，成交额1.07亿美元。消息面上，RBC此前发布研报指出，Auvelity在阿尔茨海默病激越适应症获批上市后，新处方量与总处方量出现\"统计学上显著的拐点\"，商业化进展达到或超出华尔街预期。RBC估算Q2新处方约6,300张，Q3有望增至约27,600张；总处方量则从Q2约9,200张增至Q3约37,400张。该行预计Auvelity全年收入可达8.04亿美元，上行空间达8.15亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Auvelity处方量强劲增长，Axsome盘中上涨","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111108043","title":"异动解读｜Axsome Therapeutics盘中上涨5.01%，Q2营收同比增46%盘中收复盘前跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111108043","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111108043?lang=zh_cn&edition=full","pubTime":"2026-08-11 02:58","pubTimestamp":1786388339,"startTime":"0","endTime":"0","summary":"8月10日，Axsome Therapeutics盘中上涨5.01%，报223.4美元/股，成交额2.0亿美元。公司此前盘前因Q2财报每股亏损及营收双双不及预期一度大跌逾8%，但开盘后股价快速反弹收复失地。消息面上，公司Q2实现营收2.184亿美元，同比增长46%，核心产品AUVELITY净销售额达1.803亿美元，同比增长51%，显示商业化放量势头强劲。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120099489","title":"异动解读 | Axsome Therapeutics盘前大跌8.34%，Q2财报每股亏损及营收均不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120099489","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120099489?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:38","pubTimestamp":1786361898,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.今日盘前股价大跌8.34%，引发市场关注。消息面上，公司公布的第二季度财务数据显示，GAAP每股亏损为0.99美元，较市场预期低0.10美元；当期营业收入为2.184亿美元，同比增长45.6%，但较市场一致预期少338万美元。然而，销售、研发等多项运营开支同步走高，导致整体亏损表现不及预期，后续市场将密切跟踪核心药物处方量的变化，以判断增长动能能否延续。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658933459","title":"Axsome Therapeutics（AXSM）二季度GAAP每股盈亏为0.99美元 营业收入2.184亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658933459","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658933459?lang=zh_cn&edition=full","pubTime":"2026-08-10 19:27","pubTimestamp":1786361253,"startTime":"0","endTime":"0","summary":"金吾财讯 | Axsome Therapeutics 公布第二季度财务数据，公司GAAP每股盈亏为0.99美元，较市场预期低0.10美元。当期实现营业收入2.184亿美元，同比增幅达到45.6%，但较市场一致预期少338万美元。该企业专注于中枢神经系统领域药物开发与商业化，本季度营收大幅上涨，主要来源于已上市药物的市场销售放量。不过销售、研发等多项运营开支同步走高，最终造成每股亏损不及预期。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YzM5OTgzZmE3NTA3Njg3Nzc4Mjg=.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303617","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UUP","UDN","LENZ","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116287182","title":"Axsome Therapeutics宣布FDA受理Axs-12治疗发作性睡病中猝倒症的新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1116287182","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1116287182?lang=zh_cn&edition=full","pubTime":"2026-07-15 19:02","pubTimestamp":1784113338,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics公司宣布，美国食品药品监督管理局（FDA）已正式受理其新药Axs-12用于治疗发作性睡病中猝倒症的新药申请。这一进展标志着该药物向上市迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4585","BK4505","BK4007","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105093932","title":"Axsome Therapeutics启动Solriamfetol治疗儿童注意缺陷多动障碍的Focus-2三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1105093932","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105093932?lang=zh_cn&edition=full","pubTime":"2026-07-07 19:04","pubTimestamp":1783422284,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics已正式启动其候选药物Solriamfetol针对儿童注意缺陷多动障碍的Focus-2三期临床试验。这项研究旨在评估该药物在年轻患者群体中的安全性与有效性，标志着公司在该治疗领域研发进程中的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4007","BK4585","BK4505","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132235371","title":"Axsome Therapeutics启动Solriamfetol治疗青少年注意力缺陷多动障碍的FOCUS-3三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1132235371","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132235371?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:00","pubTimestamp":1782471654,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics已正式启动其药物Solriamfetol用于治疗青少年注意力缺陷多动障碍的FOCUS-3三期临床研究。该试验旨在评估该疗法在青少年患者群体中的安全性与有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM","BK4505","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152330928","title":"异动解读 | 多家华尔街分析师上调目标价，Axsome Therapeutics盘中大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152330928","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152330928?lang=zh_cn&edition=full","pubTime":"2026-05-04 21:34","pubTimestamp":1777901649,"startTime":"0","endTime":"0","summary":"生物制药公司Axsome Therapeutics今日盘中股价大幅上涨5.03%，引起了市场参与者的关注。消息面上，多家华尔街知名券商在今日发布的研究报告中，纷纷上调了该公司的目标股价。分析师们集体上调目标价的行动，通常被视为对公司未来业绩和增长前景的积极预期，这直接提振了市场信心，推动了股价在交易时段内的强劲表现。投资者对此作出反应，导致该股在开盘后不久即出现显著上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194346361","title":"Axsome Therapeutics宣布FDA批准Auvelity®用于治疗阿尔茨海默病相关痴呆激越症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1194346361","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194346361?lang=zh_cn&edition=full","pubTime":"2026-05-01 02:08","pubTimestamp":1777572495,"startTime":"0","endTime":"0","summary":"生物制药公司Axsome Therapeutics宣布，其创新药物Auvelity®（右美沙芬氢溴酸盐与安非他酮盐酸盐复方制剂）已获得美国食品药品监督管理局（FDA）批准，用于治疗由阿尔茨海默病引起的痴呆相关的激越症状。\n此次获批标志着Auvelity®在现有适应症基础上的重要拓展，为阿尔茨海默病相关激越症状的治疗提供了新的药物选择。激越症状是痴呆患者常见的神经精神症状，对患者及其照护者的生活质量构成显著挑战。\nAuvelity®作为一种新型口服疗法，其独特的双重作用机制旨在调节与情绪和行为相关的神经递质系统。该药物的批准基于其临床试验中展现出的有效性和安全性数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4505","AXSM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186909738","title":"财报前瞻｜Axsome Therapeutics, Inc.本季度营收预计增59.11%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1186909738","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186909738?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:01","pubTimestamp":1777251719,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.将于2026年05月04日发布财报，市场聚焦营收高增与管线催化落地节奏。市场一致预期本季度营收为1.91亿美元，同比增59.11%；调整后每股收益为-0.87美元，同比改善34.74%；同时预计EBIT为-4,227.66万美元，同比改善31.23%；公司未提供本季度明确指引，毛利率与净利润或净利率的外部一致预期暂缺。公司目前主营以产品销售为核心，毛利率维持93.71%；发展前景最大的现有业务集中在产品销售板块，上季度产品收入为6.34亿美元，占比99.26%，带动公司季度总收入同比增长65.03%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Axsome Therapeutics, Inc.本季度营收预计增59.11%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518277592","title":"Axsome Therapeutics, Inc.盘中异动 急速下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518277592","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518277592?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:42","pubTimestamp":1741617767,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时42分，Axsome Therapeutics, Inc.股票出现异动，股价大幅跳水5.00%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3487.28%、761.92%、648.51%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.06%、41.36%、40.33%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224248abf31732&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224248abf31732&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","AXSM","LENZ","BK4505","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516579633","title":"Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516579633","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516579633?lang=zh_cn&edition=full","pubTime":"2025-03-03 20:51","pubTimestamp":1741006288,"startTime":"0","endTime":"0","summary":"Baird：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由132.00美元调整至160.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/03205148492765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AXSM","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514857535","title":"瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514857535","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514857535?lang=zh_cn&edition=full","pubTime":"2025-02-27 00:11","pubTimestamp":1740586273,"startTime":"0","endTime":"0","summary":"瑞穗银行：维持Axsome Therapeutics(AXSM.US)评级，由优于大市调整至优于大市评级, 目标价由195.00美元调整至212.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27001148413683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["161121","LENZ","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132091385","title":"异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1132091385","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132091385?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:04","pubTimestamp":1740510275,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics, Inc.(AXSM)今日盘中大跌5.03%,引发了市场广泛关注。\n\nAXSM是一家致力于开发治疗中枢神经系统疾病的新疗法的生物制药公司。从最新财报数据看,公司营收3.86亿美元,净利润则达-2.87亿美元,每股亏损5.99美元。较高的亏损可能是导致股价下跌的主要原因之一。\n\n同时,分析师普遍认为,该公司股价目前市盈率过高,约为-20.76倍,短期内增长动能不足,估值面临压力。机构方面给予100%买入评级,但显然并没能阻止股价下跌。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | Axsome Therapeutics盘中大跌5.03% 分析师称业绩及估值或为主因","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514139048","title":"Axsome Therapeutics, Inc.盘中异动 下午盘快速下挫5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514139048","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514139048?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:01","pubTimestamp":1740510114,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时01分，Axsome Therapeutics, Inc.股票出现异动，股价快速下跌5.04%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Silexion Therapeutics Corp涨幅较大，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1940.33%、1162.55%、995.72%，振幅较大的相关个股有Organovo Holdings, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Silexion Therapeutics Corp，振幅分别为241.19%、112.90%、87.83%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260301549892802b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502260301549892802b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","BK4505","LENZ","BK4139","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778342","title":"Axsome Therapeutics, Inc.盘中异动 早盘股价大跌5.15%报130.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778342","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513778342?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:04","pubTimestamp":1740409483,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时04分，Axsome Therapeutics, Inc.股票出现异动，股价大幅下跌5.15%。截至发稿，该股报130.65美元/股，成交量22.0085万股，换手率0.45%，振幅4.89%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。其相关个股中，Pepgen Inc.、Telix Pharmaceutic、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为160.26%、70.68%、25.66%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、42.86%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230443abdb160d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230443abdb160d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4007","LENZ","BK4139","BK4585","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513902542","title":"Axsome Therapeutics, Inc.盘中异动 快速上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513902542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513902542?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:28","pubTimestamp":1740155326,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日00时28分，Axsome Therapeutics, Inc.股票出现异动，股价大幅拉升5.02%。截至发稿，该股报135.58美元/股，成交量43.6884万股，换手率0.90%，振幅5.52%。Axsome Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Nkgen Biotech, Inc.、Invivyd, Inc.、Osr Holdings, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为201.91%、142.45%、119.77%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为70.43%、57.50%、48.19%。Axsome Therapeutics, Inc.公司简介：Axsome Therapeutics Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002847abd7c910&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222002847abd7c910&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4585","BK4139","BK4505","LENZ","AXSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513689292","title":"Axsome Therapeutics, Inc.2024财年实现净利润-2.87亿美元，同比减少20.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513689292","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513689292?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:00","pubTimestamp":1740153636,"startTime":"0","endTime":"0","summary":"2月22日，Axsome Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.87亿美元，同比减少20.08%；其中营业收入为3.86亿美元，同比增加42.44%，每股基本收益为-5.99美元。机构评级：截至2025年2月22日，当前有17家机构对Axsome Therapeutics, Inc.目标价做出预测，其中目标均价为166.47美元，其中最低目标价为121.00美元，最高目标价为200.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000053a24ec476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222000053a24ec476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AXSM","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512748730","title":"Truist Securities：维持Axsome Therapeutics(AXSM.US)评级，由买入调整至买入评级, 目标价由190.00美元调整至200.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512748730","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512748730?lang=zh_cn&edition=full","pubTime":"2025-02-20 01:11","pubTimestamp":1739985063,"startTime":"0","endTime":"0","summary":"Truist Securities：维持Axsome Therapeutics(AXSM.US)评级，由买入调整至买入评级, 目标价由190.00美元调整至200.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20011148268171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","AXSM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.axsome.com","stockEarnings":[{"period":"1week","weight":0.0209},{"period":"1month","weight":-0.232},{"period":"3month","weight":-0.334},{"period":"6month","weight":-0.1266},{"period":"1year","weight":0.2126},{"period":"ytd","weight":-0.1263}],"compareEarnings":[{"period":"1week","weight":-0.0115},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.029},{"period":"6month","weight":0.0855},{"period":"1year","weight":0.1456},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Axsome Therapeutics, Inc.成立于2012年1月。该公司是一家临床阶段的生物制药企业，开发新的治疗疼痛和其他中枢神经系统或中枢神经系统，疾病管理。通过专注于这一治疗领域，他们正在解决显著和不断增长的市场，其中目前的治疗选择是有限或不充分的。他们的目标是成为一个完全集成的生物制药公司开发和商业化的拓展提供给医护人员的治疗方案，提高生活疼痛和其他中枢神经系统疾病患者的生命分化疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.074403},{"month":2,"riseRate":0.181818,"avgChangeRate":-0.03699},{"month":3,"riseRate":0.363636,"avgChangeRate":0.055503},{"month":4,"riseRate":0.727273,"avgChangeRate":0.158416},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.036488},{"month":6,"riseRate":0.636364,"avgChangeRate":0.116789},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.037279},{"month":8,"riseRate":0.545455,"avgChangeRate":0.039835},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.02425},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.001191},{"month":11,"riseRate":0.7,"avgChangeRate":0.154442},{"month":12,"riseRate":0.727273,"avgChangeRate":0.190318}],"exchange":"NASDAQ","name":"Axsome Therapeutics, Inc.","nameEN":"Axsome Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Axsome Therapeutics, Inc.(AXSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Axsome Therapeutics, Inc.,AXSM,Axsome Therapeutics, Inc.股票,Axsome Therapeutics, Inc.股票老虎,Axsome Therapeutics, Inc.股票老虎国际,Axsome Therapeutics, Inc.行情,Axsome Therapeutics, Inc.股票行情,Axsome Therapeutics, Inc.股价,Axsome Therapeutics, Inc.股市,Axsome Therapeutics, Inc.股票价格,Axsome Therapeutics, Inc.股票交易,Axsome Therapeutics, Inc.股票购买,Axsome Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Axsome Therapeutics, Inc.(AXSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Axsome Therapeutics, Inc.(AXSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}